Order Granting the United States’ Motion to Intervene and to Dismiss, Case 1:21-cv-00008-MJT, Document 158
Summary
Order of United States District Judge Michael J. Truncale, Eastern District of Texas, Beaumont Division, in United States of America ex rel. Brook Jackson v. Ventavia Research Group, LLC; Pfizer, Inc.; ICON, PLC, Case 1:21-cv-00008-MJT, Document 158, filed 08/09/24. After the court allowed a Second Amended Complaint adding a fraudulent inducement claim, the United States moved on March 12, 2024 to intervene and dismiss under 31 U.S.C. § 3730(c)(2)(A). The court grants that motion, dismissing Counts I through IV with prejudice as to the relator and without prejudice as to the United States. It denies as moot the motions of Pfizer and Icon and grants Ventavia's motion, dismissing the FCA retaliation claim with prejudice and the Texas Health and Safety Code retaliation claim without prejudice, and closes the case.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Full text
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 1 of 25 PageID #: 5874
IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF TEXAS
BEAUMONT DIVISION
UNITED STATES OF AMERICA ex rel. §
BROOK JACKSON, §
§
Plaintiff, §
§ CIVIL ACTION NO. 1:21-CV-00008
v. § JUDGE MICHAEL J. TRUNCALE
§
VENTAVIA RESEARCH GROUP, LLC; §
PFIZER, INC.; ICON, PLC, §
§
Defendants. §
ORDER GRANTING THE UNITED STATES’ MOTION TO INTERVENE AND TO
DISMISS PURSUANT TO 31 U.S.C. § 3730(c)(2)(A) AND GRANTING VENTAVIA
RESEARCH GROUP, LLC’S MOTION TO DISMISS RELATOR’S SECOND
AMENDED COMPLAINT
Before the Court are Defendant Pfizer, Inc. (“Pfizer”)’s Motion to Dismiss Relator’s
Second Amended Complaint [Dkt. 119], Defendant Icon PLC (“Icon”)’s Motion to Dismiss
Relator’s Second Amended Complaint [Dkt. 120], Defendant Ventavia Research Group, LLC
(“Ventavia”)’s Motion to Dismiss Relator’s Second Amended Complaint [Dkt. 121], and Movant
the United States’ Motion to Intervene and to Dismiss Pursuant to 31 U.S.C. § 3730(c)(2)(A) [Dkt.
137]. The Court heard oral argument on the United States’ Motion and the Defendants’ Motions
on May 1, 2024. For the following reasons, the Court GRANTS the United States’ Motion,
DENIES AS MOOT Pfizer’s and Icon’s Motions, and GRANTS Ventavia’s Motion.
I. BACKGROUND
A. Factual Background
On May 15, 2020, the United States Government launched Operation Warp Speed, an
interagency partnership between the United States Department of Defense (“DoD”) and United
States Department of Health and Human Services (“HHS”), in an effort to accelerate the
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 2 of 25 PageID #: 5875
development, acquisition, and distribution of a COVID-19 vaccine. [Dkt. 118 at 11]. Soon
thereafter, Pfizer began working to develop a COVID-19 vaccine. See generally id.
In July 2020, while Pfizer’s vaccine was still under development, the DoD entered into a
contract (the “Project Agreement”) with Pfizer under which Pfizer would deliver 100 million doses
of a U.S. Food and Drug Administration (“FDA”) authorized or approved vaccine to the United
States Government (the “Government”) on a fixed price per dose basis in accordance with a
“Statement of Work.” [Dkt. 118-1 at 303–37]. The Statement of Work provided that if Pfizer
secured FDA approval or Emergency Use Authorization (“EUA”) for its vaccine, the Government
would pay it $1.95 billion for 100 million doses of its vaccine. Id. at 319.
After executing the Project Agreement, Pfizer endeavored to launch a clinical trial in order
gain FDA approval or EUA for its vaccine. [Dkt. 118 at 9–11]. Pfizer contracted with Icon, an
Irish clinical research organization, and Ventavia, a testing site operator, to conduct the clinical
trial. Id. at 10. Icon was charged with managing Pfizer’s clinical trial and, in turn, was responsible
for managing over 160 test sites across the globe and ensuring clinical trial protocol compliance
and required information reporting. Id. at 14. Ventavia operated three test sites—located in Keller,
Fort Worth, and Houston, Texas—as part of Pfizer’s clinical trial. Id.
On September 8, 2020, Ventavia hired Relator Brook Jackson (the “Relator”) as a Regional
Director for two of its vaccine testing sites. Id. at 68. The Relator’s direct supervisor was Director
of Operations Marnie Fisher (“Fisher”). Id. Her other supervisors were Executive Director Olivia
Ray (“Ray”), Executive Director Kristie Raney (“Raney”), and Chief Operating Officer Mercedes
Livingston (“Livingston”). Id.
From September 8, 2020 to September 25, 2020, the Relator allegedly witnessed and
“reported on a near-daily basis” numerous violations of Pfizer’s clinical trial protocol. Id. at 68–
77. Specifically, the Relator allegedly witnessed and reported the following clinical trial protocol
and FDA regulatory violations to Fisher and Livingston:
2
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 3 of 25 PageID #: 5876
(1) enrollment and injection of ineligible trial participants; (2) falsification of data,
poor recordkeeping, and the deficiency of Ventavia’s documentation “quality
control”; (3) deficiencies in and failure to obtain informed consent from trial
participants; (4) adverse event and [Serious Adverse Event] capture and reporting;
(5) failure to preserve blinding; (6) vaccine dilution errors; (7) failure to list all staff
on delegation logs; (8) principal investigator oversight; (9) reporting temperature
excursions; (10) patient safety issues, such as not keeping epinephrine dose
information in patient charts; (11) failure to secure and record staff training required
by clinical research standards; (12) use of unqualified staff as vaccinators; (13) use
of biohazard bags for needle disposal; and (14) failure to properly monitor patients
post-injection.
Id. at 68–69. The Relator alleges that each time she voiced her concerns to Fisher, she was
instructed to send Fisher an email or make a list of affected participants. Id. at 69. The Relator,
who claims she did not have access to the information needed to make the lists her supervisor
requested, asserts that she complied with Fisher’s instructions to the extent she could, but that the
issues she flagged were never addressed. Id. The Relator also reported Ventavia’s “quality
checking” practices to Fort Worth Principal Investigator Dr. Mark Koch (“Dr. Koch”) and
Ventavia management. Id. at 69–70.
On both September 14, 2020 and September 16, 2020, the Relator called Ventavia’s Pfizer
contact, Dr. Arturo Alfaro (“Dr. Alfaro”). Id. She did not reach him either time. Id. at 70.
On September 15, 2020, the Relator informed Fisher that some patient charts had not been
quality checked or sent to Pfizer. Id.
On September 16, 2020, the Relator took photographs of biohazard bags containing used
needles; HIPAA violations, namely calendars and records containing participants’ names and
information that were left out in public view; and boxes labeled with participant randomization
numbers that were left out in public view. Id. at 70–71. The Relator shared these photographs with
Fisher and Livingston via text message and email. Id. at 72.
On September 17, 2020, the Relator spoke by phone with Lovica Downs (“Downs”),
Ventavia’s Houston Regional Director, and William Jones (“Jones”), Ventavia’s Quality Control
Director. Id. When asked what would happen if the FDA audited Ventavia, they allegedly both
3
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 4 of 25 PageID #: 5877
responded that Ventavia would receive warning letters or be asked to discontinue trial enrollment.
Id.
Later that day, during a phone call with Ray, Raney, Fisher, Downs, and Livingston, the
Relator “brought up virtually all of the protocol and regulatory violations she had witnessed to
date, as well as Ventavia’s HIPAA violations.” Id. The Relator explained that “the FDA would
likely issue warning letters against Ventavia if it visited or audited the trial sites” and
recommended that Ventavia stop enrollment. Id. The Relator also sent text messages to Ray,
Raney, Fisher, Downs, and Livingston expressing concerns about Ventavia’s quality checking of
source documents and relaying concerns from the Operations Manager of Ventavia’s Fort Worth
site about protocol and HIPAA violations. Id. at 72–73.
Ventavia decided to pause enrollment on September 17, 2020, although it allegedly was
not honest with Pfizer or Icon about its reasons for doing so. Id. at 73. Despite pausing enrollment,
Ventavia allegedly failed to correct documentation violations and falsified missing or incorrect
data. Id. at 74.
On September 23, 2020, the Relator emailed Ray, Raney, Fisher, Down, Livingston, and
Jones to report issues with Ventavia’s quality checking process, namely outstanding queries from
Icon regarding missing or inconsistent data, scheduling errors resulting in late second injections, a
delay in sending a participant’s chart to Icon, and missing participant charts or laboratory
specimens. Id.
Also on September 23, 2020, the Relator emailed Livingston to report that Ventavia’s
emergency response protocol for allergic reactions was not being followed. Id. at 74–75.
On September 24, 2020, the Relator met with Fisher and Jones. Id. at 75. During this
meeting, the Relator, Fisher, and Jones discussed the Relator’s concerns regarding safety issues,
HIPAA violations, unblinding, and FDA regulations as well as the Relator’s photographic
documentation of these issues. Id. The Relator alleges that Fisher “questioned repeatedly why [the]
4
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 5 of 25 PageID #: 5878
Relator took the photographs and falsely accused [the] Relator of removing patient source
documents from another Ventavia location.” Id. The Relator suggested that Fisher and Jones “get
on Google” and search for FDA warning letters if they failed to see what she saw when quality
checking participants’ source documents. Id. at 75–76.
On September 25, 2020, the Relator “called the FDA’s hotline to report the clinical trial
protocol violations and patient safety concerns she witnessed.” Id. at 76.
Later that day, the Relator was terminated by Ventavia. Id. Ventavia’s explanation was that
the Relator was “not a good fit.” Id.
After her termination, the Relator anonymously spoke with Dr. Alfaro at Pfizer about her
concerns regarding unblinding, principal investigator oversight, and participant safety at the trial.
Id. She also informed Dr. Alfaro that she had contacted the FDA. Id.
Shortly after her termination, the FDA contacted the Relator and spoke with her for several
hours regarding the violations she witnessed while working for Ventavia. Id. at 77.
Ventavia lifted its enrollment pause on the following business day. Id. The Relator
“estimates that Ventavia had neither completed quality checking nor remedied its ongoing
violations by the time it resumed enrollment.” Id.
On November 18, 2020, Pfizer announced its clinical trial results. [Dkt. 118-1 at 290–94].
Data analysis from 41,135 trial participants showed that a two-dose regimen of the vaccine was
95% effective against COVID-19. Id. at 290–94. Safety data showed a favorable safety profile and
raised no serious safety concerns. Id. at 290–94. Pfizer asked the FDA to authorize its vaccine for
emergency use on November 20, 2020. [Dkt. 118 at 8]. The FDA granted EUA on December 11,
2020. Id. On August 23, 2021, the FDA fully approved Pfizer’s vaccine for individuals sixteen
years of age and older by granting a Biologics License Application. Id. at 12.
5
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 6 of 25 PageID #: 5879
B. Procedural Background
On January 8, 2021, the Relator filed this qui tam action against Pfizer, Icon, and Ventavia
under seal. [Dkt. 2]. The Relator’ s Original Complaint asserted presentment and false record False
Claims Act (FCA) claims against all Defendants and a single FCA retaliation claim against
Ventavia. Id.
The United States declined to intervene in this action on January 18, 2022. [Dkt. 13].
Among other things, the United States’ Notice of Election to Decline Intervention specifically
reserved the United States’ right under 31 U.S.C. § 3730(c)(3) to intervene in this action down the
road for good cause and to seek dismissal of this action. Id. On February 10, 2022, the Court
acknowledged receipt of the United States’ Notice, unsealed this action, and instructed the Relator
to serve the Defendants. [Dkt. 16]. This Order also noted that the United States “is entitled to
intervene in this action, for good cause, at any time.” Id.
The Relator subsequently filed and served Defendants with her First Amended Complaint
on February 22, 2022. [Dkt. 17; Dkt. 18]. Like her Original Complaint, the Relator’s First
Amended Complaint asserted presentment and false record FCA claims against the Defendants
and one FCA retaliation claim against Ventavia. [Dkt. 17].
All three Defendants filed Motions to Dismiss under either or both Federal Rules of Civil
Procedure 9(b) or 12(b)(6) and the United States filed a Statement of Interest Supporting Dismissal
of the Amended Complaint. [Dkt. 37; Dkt. 51; Dkt. 53; Dkt. 70].
After hearing oral argument on Defendants’ Motions, the Court granted Defendants’
Motions to Dismiss on March 31, 2023. [Dkt. 96]. The Relator’s two substantive FCA claims were
dismissed with prejudice and the Relator’s retaliation claim was dismissed without prejudice. Id.
On April 28, 2023, the Relator filed a Rule 59(e) Motion to Alter or Amend Order of
Dismissal. [Dkt. 97]. Therein, the Relator sought leave to file a second amended complaint
asserting a fraudulent inducement FCA claim against all Defendants and FCA and Texas Health
6
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 7 of 25 PageID #: 5880
and Safety Code retaliation claims against Ventavia. Id. The Court granted the Relator’s Motion
on August 9, 2023. [Dkt. 108].
The Relator filed her Second Amended Complaint on October 5, 2023. [Dkt. 118]. Count
I asserts the Relator’s new fraudulent inducement FCA claim; Counts II, III, and IV assert the
Relator’s previously dismissed substantive FCA claims solely for appellate preservation purposes;
Count V asserts the Relator’s FCA retaliation claim; and Count VI asserts the Relator’s Texas
Health and Safety Code retaliation claim. Id.
The Defendants filed their underlying Motions to Dismiss on October 20, 2023. [Dkt. 119;
Dkt. 120; Dkt. 121]. The United States filed its underlying Motion to Intervene and Dismiss on
March 12, 2024. [Dkt. 137]. The Court heard oral argument on these motions on May 1, 2024 and
is now prepared to rule on them.
II. THE UNITED STATES’ MOTION TO INTERVENE AND TO DISMISS
A. Intervention by the United States After the Seal Period
The FCA imposes civil liability on any person who presents false or fraudulent claims for
payment to the federal government. United States ex rel. Polansky v. Exec. Health Res., Inc., 599
U.S. 419, 423 (2023) (citing 31 U.S.C. §§ 3729–3733). FCA civil actions are unique in that they
can be brought by the Government or by a private party—referred to as a relator—who sues on
the Government’s behalf. Id.; 31 U.S.C. § 3730(a), (b). When a relator files a FCA complaint, it
“remain[s] under seal for at least 60 days.” 31 U.S.C. § 3730(b)(2). During this time, which is
often extended for “good cause,” the Government receives a copy of the realtor’s complaint and
supporting “material evidence” and determines whether to “intervene and proceed with the action.”
Id. § 3730(b)(2), (3). “If the Government proceeds with the action, it shall have the primary
responsibility for prosecuting the action, and shall not be bound by an act of the [relator].” Id.
§ 3730(c)(1). If, however, “the Government elects not to proceed with the action, the [relator] shall
have the right to conduct the action.” Id. § 3730(c)(3). But “even then, the realtor is not home free”
7
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 8 of 25 PageID #: 5881
because the Government is a “real party in interest” and “Congress gave the Government
continuing rights in the action.” Polansky, 599 U.S. at 425–26 (quoting United States ex rel.
Eisenstein v. City of New York, 556 U.S. 928, 930 (2009)). Most notably, “[w]hen a [relator]
proceeds with the action, the court, without limiting the status and rights of the [relator], may
nevertheless permit the Government to intervene at a later date upon a showing of good cause.”
31 U.S.C. § 3730(c)(3); see also Polansky, 599 U.S. at 426 (stating that “the Government can
intervene after the seal periods ends, so long as it shows good cause to do so”).
The Government asserts that it has good cause to intervene at this point because it wants
to dismiss the case given1 (1) its doubt as to the case’s merits, [Dkt. 137 at 7 (indicating that it has
investigated and evaluated the Relator’s claims and stating that “[w]hile a defendant’s fraud in
inducing [the] FDA to authorize or approve a product may be the basis for a viable FCA claim,
here, [the] FDA was aware of [the] Relator’s allegations of clinical trial protocol violations that
she witnessed at Ventavia prior to the initial EUA”)]; (2) its continued access to and differing
assessment of the Pfizer vaccine data, id. at 7–8; (3) the “significant burden” that continued
litigation of this case would place on it in light of “anticipated discovery and litigation obligations,”
id. at 8; and (4) its belief that it should not have “to expend resources on a case that is inconsistent
with its public health policy,” id.
The Relator argues that the Government does not have good cause to intervene because (1)
there has been no showing of good cause sufficient to overcome the extreme prejudice to the
Relator associated with the Government’s intervention and dismissal as required by Federal Rule
of Civil Procedure 24; (2) there has been no change in circumstances since the Government
1
The portion of the Government’s Motion devoted to intervention merely states that “the United States has good cause
to intervene because it seeks to dismiss Relator Jackson’s Second Amended Complaint.” [Dkt. 137 at 6]. Because the
Government’s desire to dismiss the case is informed by the Government’s arguments in the portion of its Motion
devoted to dismissal, the Court includes those arguments here. Id. at 6–8.
8
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 9 of 25 PageID #: 5882
declined to intervene; and (3) the Government’s Motion offends fundamental constitutional rights.
[Dkt. 145 at 16–28].
Because the parties disagree about what the “good cause” standard requires, the Court will
start its analysis there. In 2023, in United States ex rel. Polansky v. Executive Health Resources,
Inc., the Supreme Court shed significant light on the interplay between the Government’s right to
intervene after the seal period ends and the Government’s right to dismiss the case notwithstanding
the relator’s objections. See 599 U.S. at 423–39; see also 31 U.S.C. § 3730(c)(2)(A). Although it
did not evaluate the good cause standard, it affirmed the Third Circuit’s underlying ruling “across
the board” and “in all respects.” Polansky, 599 U.S. at 429, 439. And while the Government’s
satisfaction of the good cause standard was not challenged by the relator in Polansky and, as a
result, not addressed in depth by the Supreme Court, the Supreme Court repeated the Third
Circuit’s explanation of the good cause standard in a neutral—if not positive—manner. Id. at 429
n.2. Specifically, the Supreme Court recited the Third Circuit’s explanation that “showing ‘good
cause’ is neither a burdensome nor unfamiliar obligation,” but rather “a uniquely flexible and
capacious concept, meaning simply a legally sufficient reason.” Id. (quoting Polansky v. Exec.
Health Res. Inc., 17 F.4th 376, 387 (3d Cir. 2021)). According to the Government, this is the
standard the Court should follow here.
The Relator argues that under Rule 24(b)(3), the Court must weigh the Government’s good
cause arguments against any prejudice the Relator would experience due to the Government’s
intervention. Rule 24(b)(3) applies in the context of permissive intervention and provides that “[i]n
exercising its discretion, the court must consider whether the intervention will unduly delay or
prejudice the adjudication of the original parties’ rights.” Fed. R. Civ. P. 24(b)(3). In support of
this argument, the Relator cites United States ex rel. Precision Co. v. Koch Indus., Inc., 31 F.3d
1015 (10th Cir. 1994); United States ex rel. Drennen v. Fresnius Med. Care Holdings, Inc., No.
09-10179, 2018 U.S. Dist. LEXIS 53978 (D. Mass. Mar. 30, 2018); United States v. AseraCare
9
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 10 of 25 PageID #: 5883
Inc., No. 2:12-CV-245, 2012 U.S. Dist. LEXIS 136059 (N.D. Ala. Sept. 24, 2012); and United
States ex rel. Hall v. Schwartzman, 887 F. Supp. 60 (E.D.N.Y. 1995). Unlike Polansky, however,
none of these cases are binding on this Court. These cases also predate Polansky, which did not
mention Rule 24(b)(3) and therefore substantially undermines their persuasiveness.
Additionally, although the good cause requirement for intervention after the sealing period
technically renders the Government’s intervention permissive rather than mandatory, the Court is
not convinced that Rule 24 intervention is analogous to 31 U.S.C. § 3730 intervention. Rule 24
intervention pertains to non-parties intervening in a lawsuit. Contrastingly, 31 U.S.C. § 3730
intervention pertains to the Government, on whose behalf the relator brings the action, intervening
to prosecute the action itself. Furthermore, in the 31 U.S.C. § 3730 context, the injury asserted
belongs “exclusively” to the Government, the purpose of the action is to “vindicate the
Government’s interests,” and the relator’s right to conduct the action is always subject to the
Government’s rights, including the right to intervene down the road. Polansky, 599 at 425, 427.
438. In fact, the similarities between Rule 24 intervention and 31 U.S.C. § 3730 intervention seem
to begin and end with their use of the word “intervention.”
Given that Rule 24 does not fit these circumstances, that the cases cited by the Relator are
non-binding, and that the Supreme Court seemingly endorsed the Third’s Circuit good cause
standard, the Court will apply the good cause standard as outlined in Polansky.2 The Government,
therefore, is merely required to offer a “legally sufficient” reason to intervene. Polansky, 599 U.S.
at 429 n.2. Courts, particularly in the wake of Polansky, have consistently permitted the
2
Even if the Court were to apply Rule 24, it would find that the Government had met the good cause standard and
permit the Government to intervene. In the Fifth Circuit, “Rule 24 is to be liberally construed.” Brumfield v. Dodd,
749 F.3d 339, 341 (5th Cir. 2014). The Relator’s right to conduct this action on the Government’s behalf has always
been subject to the Government’s rights, meaning the Relator has always known that intervention was a possibility.
She chose to proceed anyway. Additionally, because discovery has been stayed, the Relator’s financial investment in
this case has been contained. Accordingly, the Court disagrees that the Relator will face “extreme prejudice” if the
Government intervenes. To the extent the Relator is prejudiced, the Court finds that the Government’s good cause
arguments outweigh that prejudice since it is the Government’s interests that are ultimately being vindicated—not the
Relator’s.
10
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 11 of 25 PageID #: 5884
Government to intervene after the seal period when the Government wants to dismiss a case
because it disputes the case’s merits, wants to avoid discovery and litigation costs, or finds that the
case conflicts with its policies. See e.g., Polansky, 599 U.S. at 428 n.2 (affirming the Third
Circuit’s decision “that the Government’s request to dismiss the suit—based on its weighing of
discovery burdens against likelihood of success—itself established good cause to intervene”);
Brutus Trading, LLC v. Standard Charter Bank, No. 20-2578, 2023 WL 5344973, at *1–2 (2d Cir.
Aug. 21, 2023) (affirming a lower court’s decision to permit the Government to intervene and
dismiss a qui tam action where the Government decided that “[the Relator’s] factual allegations
were unsupported, its legal theory was not cognizable, and the continuation of the suit would waste
considerable government resources”); United States ex rel. Carver v. Physicians Pain Specialists
of Ala., P.C., No. 22-13608, 2023 WL 4853328, at *4, 6–7 (11th Cir. July 31, 2023) (affirming the
lower court’s decision to allow the Government to intervene in and dismiss a qui tam suit where
the Relator had failed to prosecute the suit, neglected her responsibilities, burdened the
Government with discovery, and “undercut the United States’ FCA enforcement efforts”); United
States ex rel. CIMZNHCA, LLC v. UCB, Inc., 970 F.3d 835, 853–54 (7th Cir. 2020) (reversing a
lower court’s decision not to permit the Government to intervene in and dismiss a qui tam action
where the Government believed the conduct being complained of by the Relators was probably
lawful and complained that “[t]hese relators—created as investment vehicles for financial
speculators—should not be permitted to indiscriminately advance claims on behalf of the
government against an entire industry that would undermine . . . practices the federal government
has determined are . . . appropriate and beneficial to federal healthcare programs and their
beneficiaries” (internal quotation marks omitted)); United States ex rel. Sequoia Orange Co. v.
Baird-Neece Packing Corp., 151 F.3d 1139, 1142–43, 1146 (9th Cir. 1998) (affirming a lower
court’s decision to let the Government dismiss a meritorious qui tam action because the
Government had determined, among other things, that (1)“further FCA litigation over prorate
11
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 12 of 25 PageID #: 5885
violations” was “harmful to the [citrus] industry as a whole” and (2) continued litigation expenses
would burden taxpayers); United States ex rel. Vanderlan v. Jackson HMA, LLC, No. 3:15-CV-
767, at *6 (S.D. Miss. Apr. 12, 2024) (allowing the Government to dismiss a qui tam action
because of “the potential for continued (or increased) demand on [the Government’s] resources
and time,” among other things); United States ex rel. Toomer v. TerraPower, LLC, No. 4:16-cv-
00226, 2018 WL 4934070, at *4–5 (D. Idaho Oct. 10, 2018) (allowing the Government to dismiss
a qui tam case where the Relator simply “disagree[d] with the government’s priorities” and where
the Government doubted the case’s merits, did not want to “waste substantial government time
and resources” due to continued litigation, and feared that the case would impair future public-
private partnerships).3 Therefore, the Court, recognizing that the Government’s interest is the
predominant one, finds that the Government’s desire to dismiss the case—because of its doubt as
to the case’s merits, differing assessment of the Pfizer vaccine data, desire to avoid discovery and
litigation obligations, and belief that it should not have to expend resources in a case that is contrary
to its public health policy—constitutes good cause to intervene.
The Court turns now to the Relator’s other objections. First, the Court disagrees with the
Relator’s assertion that the Government can only intervene after the seal period “when changed
circumstances warrant a change in its intervention decision.” [Dkt. 145 at 19–22]. That is not what
31 U.S.C. § 3730(c)(3) states. Indeed, it unambiguously permits the Government to intervene at a
later stage “upon a showing of good cause.” 31 U.S.C. § 3730(c)(3). At no point does the statue
indicate that good cause requires changed circumstances. See id. Additionally, Polansky merely
indicates that Congress “knew that circumstances could change and new information come to
light” in describing why Congress passed a provision permitting late intervention. 599 U.S. at 435
(citing S. Rep. No. 99–345, p. 26 (1986)). Nothing about that statement—or Polansky as a whole—
3
The Court includes cases where only dismissal is at issue because the Government’s desire to dismiss a qui tam case
is frequently intertwined with its desire to intervene. The Court also includes dismissal-only cases because courts often
construe the Government’s motions to dismiss a qui tam case as motions to intervene.
12
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 13 of 25 PageID #: 5886
supports requiring changed circumstances for late intervention by the Government. See generally
id. The Relator also invokes the Department of Justice (“DOJ”)’s 2018 memorandum entitled,
“Factors for Evaluating Dismissal Pursuant to 31 U.S.C. § 3730(c)(2)(A)” in support of her
position that a change in circumstances is required. But the memorandum’s remark that “there may
be cases where dismissal is warranted at a later stage, particularly when there has been a significant
intervening change in the law or evidentiary record” does not in any way indicate that the
Government can only move for intervention after changed circumstances. See U.S. Dep’t of Just.,
Factors for Evaluating Dismissal Pursuant to 31 U.S.C. 3730(c)(2)(A) (Jan. 10, 2018). This
memorandum also explicitly states that it is a “general framework.” Id. Nothing about it binds the
Government or alters 31 U.S.C. § 3730(c)(3)’s requirement for “good cause.” In any case, this
memorandum arguably supports the Government’s position and undermines the Relator’s. Id.
(identifying eliminating meritless cases, preventing interference with agency policies and
programs, and preserving government resources as factors the Government has relied upon in
dismissing qui tam actions); see also United States v. Eli Lilly & Co., 4 F.4th 255, 268–69 (5th
Cir. 2021) (characterizing this memorandum as “guidance” and finding that it “cannot say that the
government did not follow its own guidance when it decided to take a risk contemplated by that
guidance”).
Moreover, circumstances have changed since the Government declined to intervene. For
example, the Relator’s First Amended Complaint was dismissed with the Government’s support.
[Dkt. 70; Dkt. 96]. The Relator filed a Second Amended Complaint, which the Government clearly
also wants dismissed. [Dkt. 137]. The Government has also expended resources monitoring the
case since it declined to intervene and faces the prospect of expending further resources should the
case survive and discovery begin. Id. The Government has also received additional data on the
Pfizer vaccine since it declined to intervene that seemingly supports its position that the Relator’s
case lacks merit and undermines its public health policy. Id. at 7–8.
13
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 14 of 25 PageID #: 5887
Second, contrary to the Relator’s assertions, the Court finds that the Government’s Motion
does not offend fundamental constitutional rights. See Polansky, 599 U.S. at 436 n.4 (noting the
Third Circuit’s statement that the Government’s efforts to dismiss a qui tam action “rest atop the
foundation of bedrock constitutional constraints on Government action,” but not “consider[ing]
the circumstances in which, or procedures by which, a court should find the Constitution to prevent
the Government from dismissing a qui tam action”). The Relator first claims that the Government’s
motion runs afoul of her First Amendment right to petition the government. [Dkt. 145 at 24–26].
But the First Amendment does not give the Relator the right to petition the government on the
United States’ behalf—only her own. See U.S. Const. amend. I. Additionally, to the extent that the
FCA gives her the right to petition the government on the United States’ behalf, that right is, as
previously discussed, substantially limited by the United States’ own rights over a qui tam action.
See 31 U.S.C. § 3730.
The Relator’s separation of powers argument likewise falls short because it ignores
Polansky and is based on pure speculation. In Polansky, the Supreme Court explicitly stated that
“the Government’s views are entitled to substantial deference” when it comes to dismissal of a qui
tam action.4 599 U.S. at 437. It further stated that “a district court should think several times over
before denying a motion to dismiss” and that [i]f the Government offers a reasonable argument for
why the burdens of continued litigation outweigh its benefits, the court should grant the motion”—
“even if the relator presents a credible assessment to the contrary.” Id. at 437–38. Given this
binding precedent, Congress’s inclusion of a late intervention provision in the FCA, and case law
permitting the Government to intervene in similar situations, the Court is unclear how allowing to
the Government to intervene here violates separation of powers principles and constitutes an
abdication of judicial power. See [Dkt. 145 at 27]. In any case, the Relator offers nothing but
4
See infra note 3 (describing why the Court relies on cases regarding dismissal when discussing intervention).
14
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 15 of 25 PageID #: 5888
speculation in support of this argument. The Government has offered frequently cited and
reasonable grounds for intervening and dismissing this case. The Relator has hardly shown that
these reasons are a façade for protecting executive officials’ personal interests.
The Relator’s argument that the Government’s motion to intervene should be denied on
substantive due process and equal protection grounds because it is arbitrary, capricious, and
perpetrates a fraud on this Court also fails. Although the Supreme Court did not touch on this
matter in Polansky, the Third Circuit did. It stated that “[o]nly the most egregious official conduct
can be said to be arbitrary in the constitutional sense” and that in this context “the constitutional
question would not be whether the Government adequately weighed the costs and benefits of its
actions, but whether there was ‘executive abuse of power’ that ‘shocks the conscience.’” Polansky,
17 F.4th at 390 n.17 (quoting Cnty. of Sacramento v. Lewis, 523 U.S. 833, 846 (1998)). The
Government provided multiple reasons for its desire to intervene in this case. As outlined above,
courts have frequently permitted intervention and dismissal for the reasons identified by the
Government here, even when a relator believes the case has merit. Contrary to the Relator’s
assertions, the Government’s reasons are also consistent with the factors identified in the DOJ’s
memorandum. Finally, there is no indication beyond the Relator’s conjecture that the
Government’s desire to intervene is due to “fraud, illegality, or lack or political will.” See [Dkt.
149 at 2]. The Relator’s differing perspective on the Pfizer vaccine data and the merits of this
action are insufficient to establish that the Government’s reasons for intervening and seeking
dismissal are arbitrary, capricious, and fraudulent. See Toomer, 2018 WL 4934070, at *5; see also
Sequoia Orange Co., 151 F.3d at 1146–47.
Accordingly, the Court holds that the Government has good cause to intervene in this case
pursuant to 31 U.S.C. § 3730(c)(3) and GRANTS the Government’s Motion to Intervene.
15
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 16 of 25 PageID #: 5889
B. Dismissal
The Court turns now to the Government’s Motion to Dismiss. 31 U.S.C. § 3730(c)(2)(A)
provides that “[t]he Government may dismiss [a qui tam] action notwithstanding the objections of
the [relator] if the [relator] has been notified by the Government of the filing of the motion and the
court has provided the person with an opportunity for a hearing on the motion.” 31 U.S.C.
§ 3730(c)(2)(A). Polansky held that Federal Rule of Civil Procedure 41 applies to the
Government’s efforts to dismiss a qui tam action subject to 31 U.S.C. § 3730(c)(2)(A)’s procedural
requirements for notice and a hearing. 599 U.S. at 435–36. The Supreme Court stated that 31
U.S.C. § 3730(c)(2)(A) motions to dismiss “will satisfy Rule 41 in all but the most exceptional
cases.” 559 U.S. at 437. It further explained that “the Government’s views are entitled to
substantial deference” in this context and that “a district court should think several times over
before denying a motion to dismiss.” Id. at 437–38. In fact, the Supreme Court instructed that “[i]f
the Government offers a reasonable argument for why the burdens of continued litigation outweigh
its benefits, the court should grant the motion.” Id. at 438. This is so “even if the relator presents
a credible assessment to the contrary.” Id.
Both the Government and the Relator agree that Defendants have not filed answers or
motions for summary judgment and that, as a result, Rule 41(a)(1)(A)(i) applies. Rule
41(a)(1)(A)(i) states that “the plaintiff may dismiss an action without a court order by filing . . . a
notice of dismissal before the opposing party serves either an answer or a motion for summary
judgment.” Fed. R. Civ. P. 41(a)(1)(A)(i). When dismissal is sought before an answer or motion
for summary judgment are filed, Rule 41(a)(1)(A)(i) “entitles the [Government] to a dismissal”
and “the district court has no adjudicatory role.” Polansky, 599 U.S. at 436 n.4.
The only question remaining is whether 31 U.S.C. § 3730(c)(2)(A)’s procedural
requirements have been satisfied. The Relator received notice of the Government’s Motion to
Dismiss when it was filed. Whether the hearing requirement has been satisfied is a tougher question
16
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 17 of 25 PageID #: 5890
because neither the statute nor Polansky specify the type of hearing required. See 31 U.S.C.
§ 3730(c)(2)(A) (stating only that “an opportunity for a hearing on the motion” is required);
Polansky, 599 U.S. 436 n.4 (indicating that “a hearing, whether pre- or post-answer, might inquire
into allegations that a dismissal ‘violate[s] the relator’s right to due process or equal protection,’”
but opting not to consider the contours of the hearing requirement since that issue was not raised
by the relator (alteration in original) (emphasis added)). The Fifth Circuit considered this question,
albeit without the benefit of Polansky. See Eli Lilly & Co., 4 F.4th at 262–63. Specifically, it
“construe[d] the term ‘hearing’ in 31 U.S.C. § 3730(c)(2)(A) to require something more than a
forum for a relator to convince the government not to dismiss” and noted that “[i]t includes judicial
involvement and action.” Id. at 262–64. The Fifth Circuit stopped short, however, of requiring an
evidentiary hearing. Id. at 265–67 (finding that the relator’s right to a hearing was satisfied without
determining that an evidentiary hearing was required because the relator opted not to present
evidence at the hearing held). Additionally, while not binding precedent, several courts have found
31 U.S.C. § 3730(c)(2)(A)’s hearing requirement satisfied by briefing alone or by non-evidentiary
hearings, particularly in Polansky’s wake. See Brutus Trading, LLC, 2023 WL 5344973, at *2
(interpreting Polansky as requiring a district court to “exercise some degree of scrutiny in
evaluating the government’s motion to dismiss” and, in turn, finding that the district court satisfied
the hearing requirement by “carefully considering the parties’ written submissions”); Borzilleri v.
Bayer Healthcare Pharms., Inc., 24 F.4th 32, 39–40 (1st Cir. 2022) (holding that the hearing
requirement “contemplates a judicial judgment of some kind, providing a level or protection for
the relator’s interest in the suit”); Vanderlan, No. 3:15-CV-767, at *5, 7–8 (reasoning that the
hearing required by 31 U.S.C. § 3730(c)(2)(A) in the Rule 41(a)(1) context cannot be more
onerous than the hearing required in the Rule 41(a)(2) context; noting that neither Polansky or 31
U.S.C. § 3730(c)(2)(A) support requiring an evidentiary hearing; and finding that a hearing to
consider whether the Government had provided a reasonable basis for dismissal satisfied the
17
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 18 of 25 PageID #: 5891
hearing requirement);5 United States ex rel. Sargent v. McDonough, No. 1:23-cv-00328, 2024 WL
809902, at *2 (D. Maine Feb. 26, 2024) (finding that a hearing is not necessary because “there is
no actual prospect that [the relator] would reveal at a further hearing how dismissal of Count I will
expose him to a constitutional injury”); Toomer, 2018 WL 4934070, at *6 (denying a relator’s
request for discovery and a hearing because the relator’s constitutional arguments are speculative
and because allowing the relator to present this evidence “may amount to an unjustified ‘mini-
trial’ on the merits of this case”).
Although evidence was not put on during the May 1, 2024 hearing, the Court finds that an
evidentiary hearing is not required by 31 U.S.C. § 3730(c)(2)(A). In any case, the Government
cited a Journal of the American Medical Association editorial in its Motion [Dkt. 137 at 8] and the
Relator submitted affidavits in support of its Response [Dkt. 145-1; Dkt. 145-2], so there was at
least some evidence before the Court. At the hearing, the Court heard arguments from the
Government, the Relator, and the Defendants. It also asked counsel numerous questions regarding
their positions, including on the Government’s reasons for wanting to intervene and dismiss the
case and on the Relator’s opposition to the Government’s motion and constitutional arguments.
The hearing was certainly more than a forum in which the Relator could try to convince the
Government not to dismiss its FCA lawsuit and involved “judicial involvement and action.” See
Eli Lilly & Co., 4 F.4th at 262–64. Additionally, both before and after the hearing, the Court spent
significant time considering the Government and the Relator’s briefs and the cases cited therein.
The Court holds that this is sufficient to satisfy 31 U.S.C. § 3730(c)(2)(A)’s hearing requirement.
Because 31 U.S.C. § 3730(c)(2)(A)’s and Rule 41(a)(1)(A)(i)’s requirements are satisfied
and because the Government offers a reasonable explanation for its desire to dismiss the action,
5
In Vanderlan, the court also noted that 31 U.S.C. § 3730(c)(2)(A)’s legislative history did not support construing the
hearing requirement as mandating an evidentiary hearing. No. 3:15-CV-767, at *8 (describing how an earlier, unpassed
version of the FCA permitted relators to file objections and request an evidentiary hearing without guaranteeing such
hearings). The Court finds this argument particularly compelling since, as the Vanderlan court points out, the enacted
version of 31 U.S.C. § 3730(c)(2)(A) “dropped all reference to an evidentiary hearing right or the right to object.” Id.
18
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 19 of 25 PageID #: 5892
dismissal is warranted. The reasons proffered by the Government for dismissal are amply
supported by case law and, pursuant to Polansky, are entitled to substantial deference. The
Government’s Motion to Dismiss is therefore GRANTED. As a result, Counts I through IV in the
Relator’s Second Amended Complaint are DISMISSED WITH PREJUDICE as to the Relator
and DISMISSED WITHOUT PREJUDICE as to the Government.6 As no claims remain against
Defendants Pfizer and Icon, their Motions to Dismiss are DENIED AS MOOT.
III. VENTAVIA RESEARCH GROUP LLC’S MOTION TO DISMISS
Although the Government’s dismissal of Counts I through IV eliminates the substantive
FCA claims against Ventavia, the Relator’s FCA and state-law retaliation claims against Ventavia
remain. Ventavia argues that the Relator has failed to state claims upon which relief can be granted
under the FCA or the Texas Health and Safety Code. The Court address the Relator’s retaliation
claims in turn.
A. Legal Standard
Federal Rule of Civil Procedure 12(b)(6) authorizes dismissal of a complaint for “failure
to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). In reviewing a Rule
12(b)(6) motion, the Court “accepts all well-pleaded facts as true, viewing them in the light most
favorable to the plaintiff.” Sonnier v. State Farm Mut. Auto. Ins. Co., 509 F.3d 673, 675 (5th Cir.
2007). While the Court must accept the well-pleaded facts in the complaint as true, it will “not
accept as true conclusory allegations, unwarranted factual inferences, or legal conclusions.”
Gentilello v. Rege, 627 F.3d 540, 544 (5th Cir. 2010).
To survive a Rule 12(b)(6) motion to dismiss, a complaint must contain enough well-
pleaded facts “to state a claim to relief that is plausible on its face.” Ashcroft v. Iqbal, 556 U.S.
6
Rule 41(a)(1)(B) provides that “[u]nless the notice or stipulation state otherwise, the dismissal is without prejudice.”
Fed. R. Civ. P. 41(a)(1)(B). The Government’s proposed order requests that the substantive FCA claims be dismissed
with prejudice as to the Relator and without prejudice as to the Government, so the Court structures its dismissal
accordingly. See [Dkt. 137-1].
19
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 20 of 25 PageID #: 5893
662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)); see Fed. R. Civ.
P. 8(a)(2) (“A pleading that states a claim for relief must contain: . . . a short and plain statement
of the claim showing that the pleader is entitled to relief . . . .”). A claim is “plausible on its face”
when the well-pleaded facts allow the Court to “draw the reasonable inference that the defendant
is liable for the misconduct alleged.” Iqbal, 556 U.S. at 678. “Where a complaint pleads facts that
are ‘merely consistent with’ a defendant’s liability, it ‘stops short of the line between possibility
and plausibility of entitlement to relief.’” Id. (quoting Twombly, 550 U.S. at 557). Determining
whether a complaint states a plausible claim for relief is “a context-specific task that requires the
reviewing court to draw on its judicial experience and common sense.” Id. at 679.
B. The Relator’s False Claims Act Retaliation Claim
The Relator alleges that Ventavia retaliated against her in violation of 31 U.S.C. § 3730(h)
“because of her efforts to stop Defendants from committing violations of the False Claims Act.”
[Dkt. 118 at 68, 92]. Specifically, she asserts that Ventavia retaliated against her for engaging in
protected activity through harassment, termination, and slander. Id. at 92.
“The ‘whistleblower’ provision of the [FCA] prevents the harassment, retaliation, or
threatening of employees who assist in or bring qui tam actions.” Robertson v. Bell Helicopter
Textron, Inc., 32 F.3d 948, 951 (5th Cir. 1994). The statute provides:
Any employee, contractor, or agent shall be entitled to all relief necessary to make
that employee, contractor, or agent whole, if that employee, contractor, or agent is
discharged, demoted, suspended, threatened, harassed, or in any other manner
discriminated against in the terms and conditions of employment because of lawful
acts done by the employee, contractor, agent or associated others in furtherance of
an action under this section or other efforts to stop 1 or more violations of this
subchapter.
31 U.S.C. § 3730(h)(1). “To establish a claim under § 3730(h), a party must show (1) that she was
engaged in protected activity with respect to the [FCA]; (2) that her employer knew she was
engaged in protected activity; and (3) that she was discharged because she was engaged in
20
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 21 of 25 PageID #: 5894
protected activity.” Thomas v. ITT Educ. Servs., Inc., 517 F. App’x 259, 262 (5th Cir. 2013) (citing
Robertson, 32 F.3d at 951).
“A protected activity is one motivated by a concern regarding fraud against the
government.” Id.; United States ex rel. Johnson v. Kaner Med. Grp., P.A., 641 F. App’x 391, 395
(5th Cir. 2016) (“To qualify as protected activity under the whistleblower provision, the activity
must be ‘in furtherance of’ uncovering fraud or potential fraud against the Government.” (citing
31 U.S.C. § 3730(h)(1))). Mere criticism by an employee of the employer’s methods of conducting
business, “without any suggestion that the [employee] was attempting to expose illegality or fraud
within the meaning of the FCA, does not rise to the level of protected activity.” United States ex
rel. Patton v. Shaw Servs., L.L.C., 418 F. App’x 366, 372 (5th Cir. 2011).
The Court previously dismissed the Relator’s FCA retaliation claim because she failed to
allege that she complained to Ventavia or the FDA about fraud against the government as opposed
to participant safety and regulatory, protocol, and HIPAA violations and, thus, failed to allege that
she engaged in protected activity. [Dkt. 96 at 46, 48]. The Court also dismissed the Relator’s FCA
retaliation claim on the grounds that she failed to allege that Ventavia knew she engaged in
protected activity. Id. at 48. Although the Court allowed the Relator to replead her FCA retaliation
claim and fix these issues, she has not done so. See [Dkt. 108]. Compare [Dkt. 17 at 60–70, 78],
with [Dkt. 118 at 68–77, 92]. In fact, the Relator’s retaliation allegations in her First Amended
Complaint and Second Amended Complaint are nearly identical. Compare [Dkt. 17 at 60–70, 78],
with [Dkt. 118 at 68–77, 92]. Although she rewords certain sentences, none of her wordsmithing
changes the substance of her allegations. She does not include any new factual allegations
indicating that she complained to Ventavia or the FDA about fraud against the government. She
also does not include any new factual allegations suggesting that Ventavia was aware of any
alleged protected activity.
21
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 22 of 25 PageID #: 5895
In her Response to Ventavia’s Motion to Dismiss, the Relator claims that “there should be
no question that [she] alleges a good faith belief that her efforts were to stop a violation” because
her FCA fraud-in-the-inducement theory is that “the departure from protocol and violation of
scientific methods was to fraudulently induce the FDA to issue the EUA, which in turn, was a
material condition for payment on the contract.” [Dkt. 127 at 31]. She also argues that her
motivations cannot properly be determined at the pleadings stage because the issue requires that a
record be built. Id. Finally, she asserts that her Second Amended Complaint makes it clear that
Ventavia knew about her protected activity because she consistently voiced her concerns about
clinical trial and FDA regulatory violations and because Ventavia acknowledged that an FDA audit
“would be bad for the company because . . . Ventavia knew a fraud was being committed on the
Government in order to acquire the EUA.” Id. at 31–32.
As Ventavia points out in its Reply, a “complaint may not be amended by the briefs in
opposition to a motion to dismiss.” Energy Coal v. CITGO Petroleum Corp., 836 F.3d 457, 462
n.4 (5th Cir. 2016) (quoting Roebuck v. Dothan Sec., Inc., 515 F. App’x 276, 280 (5th Cir. 2013)).
In any case, none of the Relator’s rationalizations cure the shortcomings of her Second Amended
Complaint. The Fifth Circuit’s requirements regarding protected activity and employer knowledge
of protected activity are very clear. This Court was very clear with the Relator as to the problems
with her FCA retaliation claim. For whatever reason the Relator made no substantive changes to
her FCA retaliation allegations. As a result, she once again has not plausibly plead that she engaged
in protected activity or that Ventavia was aware of her protected activity. The Court therefore
GRANTS Ventavia’s Motion to Dismiss and DISMISSES Count V, the Relator’s FCA retaliation
claim, WITH PREJUDICE.
C. The Relator’s Texas Health and Safety Code Retaliation Claim
The Relator alleges that Ventavia retaliated against her in violation of Texas Health and
Safety Code § 161.134 “because of her efforts to stop Defendants from committing violations of
22
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 23 of 25 PageID #: 5896
Federal Acquisition Regulations and Texas state law.” [Dkt. 118 at 92]. Specifically, she asserts
that Ventavia retaliated against her for engaging in protected activity through harassment,
termination, and slander. Id. at 92.
Because the Court has dismissed all claims over which it has original jurisdiction, the Court
must first decide whether to exercise supplemental jurisdiction over the Relator’s Texas Health
and Safety Code retaliation claim. 28 U.S.C. § 1367(a) provides that “district courts shall have
supplemental jurisdiction over all other claims that are so related to claims in the action within
such original jurisdiction that they form part of the same case or controversy under Article III of
the United States Constitution.” 28 U.S.C. § 1367(a). The Court, however, may decide not to
exercise its powers of supplemental jurisdiction if: (1) “the claim raises a novel or complex issue
of State law”; (2) “the claim substantially predominates over the claim or claims over which the
district court has original jurisdiction”; (3) “the district court has dismissed all claims over which
it has original jurisdiction”; or (4) “in exceptional circumstances, there are other compelling
reasons for declining jurisdiction.” Id. § 1367(c). In determining whether to exercise supplemental
jurisdiction, courts “must consider the provisions of 28 U.S.C. § 1367(c) and ‘weigh in each case,
and at every stage of the litigation, the values of judicial economy, convenience, fairness, and
comity.”” Hanak v. Talon Ins. Agency, Ltd., 470 F. Supp. 2d 695, 707 (E.D. Tex. 2006) (Carnegie-
Mellon Univ. v. Cohill, 484 U.S. 343, 350 (1988)).
Where, as here, all federal claims have been dismissed before trial, the Supreme Court has
counseled that a court should decline jurisdiction. Robertson v. Neuromedical Ctr., 161 F.3d 292,
296 (5th Cir. 1998) (quoting United Mine Workers of Am. v. Gibbs, 383 U.S. 715, 726 (1966)).
Within the Fifth Circuit, the “general rule is to dismiss state claims when the federal claims to
which they are pendant are dismissed.” Parker v. Parsley Petroleum Co. v. Dresser Indus., 972
F.2d 580, 585 (5th Cir. 1992) (citing Wong v. Stripling, 881 F.2d 200, 204 (5th Cir. 1989)); see
also Smith v. Amedisys Inc., 298 F.3d 434, 446–47 (5th Cir. 2002). “[T]his rule is neither
23
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 24 of 25 PageID #: 5897
mandatory nor absolute,” though. Smith, 298 F.3d at 447 (quoting Batiste v. Island Records, Inc.,
179 F.3d 217, 227 (1999)).
All of the Relator’s federal claims have been dismissed. Additionally, this case is still at
the pleading stage, no discovery has been conducted, and trial is not scheduled until December 8,
2025. Because the federal claims have been dismissed well before trial, the factors of judicial
economy, convenience, fairness, and comity suggest that this Court should decline to exercise
jurisdiction over the Relator’s state-law retaliation claim. Accordingly, the Court GRANTS
Ventavia’s Motion to Dismiss and DISMISSES the Relator’s Texas Health and Safety Code
retaliation claim WITHOUT PREJUDICE for lack of subject matter jurisdiction.
IV. LEAVE TO AMEND
The Relator requests leave to amend if the Court finds any deficiencies in the Relator’s
Second Amended Complaint as well as leave to amend to add a common law tort of wrongful
discharge. [Dkt. 127 at 35, 39]. Because the Government has intervened and dismissed Counts I
through IV with prejudice as to the Relator, the Court will not permit the Relator to amend her
complaint as to those claims. Because the Relator did not even remotely utilize her previous
opportunity to amend her FCA retaliation claim and because the Relator has already amended her
complaint, including her FCA retaliation claim, twice, the Court will not allow the Relator to
amend her complaint as to that claim. See Jack v. Evonik Corp., 79 F.4th 547, 564–65 (5th Cir.
2023) (stating that leave to amend is governed by Federal Rule of Civil Procedure 15(a)(2) and
should be “freely given” unless there is (1) “undue delay,” (2) “bad faith or dilatory motive on the
part of the movant,” (3) “repeated failure to cure deficiencies by amendments previously allowed,”
(4) “undue prejudice to the opposing party by allowing the amendment,” or (5) “futility of
amendment”); Herrmann Holdings Ltd. v. Lucent Techs Inc., 302 F.3d 552, 566–67 (5th Cir. 2022)
(finding that the district court did not abuse its discretion in denying leave to amend where
plaintiffs had already amended their complaint twice). Finally, because there are no remaining
24
Case 1:21-cv-00008-MJT Document 158 Filed 08/09/24 Page 25 of 25 PageID #: 5898
federal claims and the Court has declined to exercise supplemental jurisdiction over the Relator’s
Texas Health and Safety Code retaliation claim, the Court will not permit the Relator to amend
Count VI or to amend her complaint to add a state common law tort of wrongful discharge claim.
V. CONCLUSION
It is therefore ORDERED that Movant the United States’ Motion to Intervene and to
Dismiss Pursuant to 31 U.S.C. § 3730(c)(2)(A) [Dkt. 137] is GRANTED. As a result, the claims
outlined in Counts I through IV of Relator Brook Jackson’s Second Amended Complaint are
DISMISSED WITH PREJUDICE as to the Relator and DISMISSED WITHOUT
PREJUDICE as to the United States.
It is further ORDERED that Defendant Pfizer, Inc.’s Motion to Dismiss Relator’s Second
Amended Complaint [Dkt. 119] is DENIED AS MOOT.
It is further ORDERED that Defendant Icon PLC’s Motion to Dismiss Relator’s Second
Amended Complaint [Dkt. 120] is DENIED AS MOOT.
It is further ORDERED that Defendant Ventavia Research Group, LLC’s Motion to
Dismiss Relator’s Second Amended Complaint [Dkt. 121] is GRANTED. The claim outlined in
Count V of Relator Brook Jackson’s Second Amended Complaint is DISMISSED WITH
PREJUDICE. The claim outlined in Count VI of Relator Brook Jackson’s Second Amended
Complaint is DISMISSED WITHOUT PREJUDICE.
It is further ORDERED that all Court dates and deadlines are hereby VACATED. The
Clerk is INSTRUCTED to close this matter.
SIGNED this 9th day of August, 2024.
____________________________
Michael J. Truncale
United States District Judge
25
File and source
- File
- c02-36.pdf
- Size
- 404,229 bytes
- SHA-256
- 33745e57e50e299fe80272c65bad6bf6bbc7e72ee60e4a9246ad8a2cc66306e9
- Our copy
- c02-36.pdf
- Original
- storage.courtlistener.com